#United States #New Orleans #Kahn Swick #Sarepta Therapeutics #ELEVIDYS

Investigation into Sarepta Therapeutics Officers

In a significant step towards corporate accountability, the law firm Kahn Swick & Foti, LLC (KSF), led by former Louisiana Attorney General Charles C. Foti, Jr., has initiated an investigation into Sarepta Therapeutics, Inc. (NasdaqGS: SRPT). This probe comes in the wake of alarming allegations regarding Sarepta's flagship treatment, Elevidys, which is marketed for patients suffering from Duchenne muscular dystrophy, a serious rare disease.

Context of the Investigation

Sarepta Therapeutics, a biopharmaceutical company, has primarily focused on developing vital treatments for rare diseases. However, in March 2025, the company released troubling news about the death of a 16-year-old patient due to acute liver failure after receiving treatment with Elevidys. Despite this tragedy, Sarepta maintained that the overall benefits of the treatment outweighed its associated risks.

Following the initial incident, further incidents escalated the concerns. By June 2025, the company reported the deaths of two additional patients from similar complications linked to Elevidys. In light of these continuing incidents, Sarepta ordered a suspension of certain shipments of the drug and halted dosing in an active clinical trial. This drew significant scrutiny from investors and regulatory bodies, subsequently leading to the filing of a securities class action lawsuit against the company and its executives.

Allegations of Misconduct

The crux of KSF’s investigation centers on whether any breaches of fiduciary duties occurred among Sarepta's executives and directors, as well as potential violations of federal securities laws. The focus is on determining if there was a willful failure to disclose critical information that could influence the decisions of stakeholders during the time these serious events unfolded.

This scrutiny is particularly poignant as allegations surface suggesting that Sarepta knowingly misled investors regarding the safety profile of Elevidys. To ensure transparency, shareholders along with potential claimants are encouraged to reach out to KSF, which is offering its resources to investigate these claims thoroughly.

The Path Forward

KSF’s investigation aims to clarify the responsibilities of Sarepta's leadership and their adherence to both state and federal regulatory standards. The firm is inviting long-term shareholders of Sarepta to step forward and provide any pertinent information they might have regarding their experiences and insights into the company’s operations.

For those wishing to participate, KSF has provided contact avenues to make it easier for individuals to express their legal rights or concerns. Investors are encouraged to utilize the toll-free number or email KSF directly for further information.

About Kahn Swick & Foti, LLC

Recognized as one of the leading firms in securities litigation, KSF boasts a strong reputation for advocating for the rights of affected investors. This recognition is underscored by their impressive rankings in settlement values over the past year, solidifying their stature in the legal landscape surrounding corporate fraud and malfeasance.

With offices strategically located across the United States, KSF is well-equipped to handle complex litigation and advocate for fair treatment of shareholders nationwide.

As this investigation unfolds, the outcomes may have enduring implications for both Sarepta Therapeutics and the broader biopharmaceutical industry, emphasizing the critical need for accountability and transparency in corporate governance.